Breadcrumbs

Respiratory - oncology

Mesothelioma

Protocol Administration at chemotherapy unit level Review date
Mesothelioma cARBOplatin and pemetrexed Medium June 2022
Mesothelioma cISplatin and pemetrexed Medium June 2022
Mesothelioma vinORELBine Medium March 2021

Non small cell lung cancer

Protocol Administration at chemotherapy unit level Review date
Non small cell lung cancer locally advanced durvalumab
Low March 2022
Non small cell lung cancer locally advanced or metastatic alectinib
Low
June 2022
Non small cell lung cancer locally advanced or metastatic Atezolizumab

Medium March 2022
Non small cell lung cancer locally advanced or metastatic osimertinib
Low
March 2022
Non small cell lung cancer adjuvant cISplatin and vinORELBine Medium September 2022
Non small cell lung cancer locally advanced definitive cARBOplatin and PACLItaxel chemoradiation Medium 3 March 2022
Non small cell lung cancer advanced or metastatic nivolumab (weight based dosing) Low June 2022
Non small cell lung cancer advanced or metastatic Nivolumab (flat dosing)
Low June 2022
Non small cell lung cancer definitive cISplatin and etoposide chemoradiation Medium 3 March 2021

Non small cell lung cancer metastatic ABCP (Atezolizumab Bevacizumab Paclitaxel cARBOplatin)
For information on this protocol please contact the SA Health Cancer Drug Committee

Medium September 2020
Non small cell lung cancer metastatic afatinib Low March 2022
Non small cell lung cancer metastatic cARBOplatin and DOCEtaxel Medium March 2020
Non small cell lung cancer metastatic cARBOplatin and gemcitabine

Medium Day 1 Low day 8

September 2020
Non small cell lung cancer metastatic cARBOplatin and weekly PACLItaxel Medium March 2020
Non small cell lung cancer metastatic cARBOplatin and vinORELBine Medium September 2022
Non small cell lung cancer metastatic cARBOplatin and PACLItaxel 
Medium March 2021
Non small cell lung cancer metastatic cARBOplatin PACLitaxel and pembrolizumab
Medium September 2022
Non small cell lung cancer metastatic cARBOplatin PACLitaxel atezolizumab and bevacizumab
Medium. Moves to low risk after completion of cARBOplatin/PACLitaxel treatment September 2022
Non small cell lung cancer metastatic cARBOplatin, pemetrexed and pembrolizumab
Medium June 2022
Non small cell lung cancer metastatic cISplatin and gemcitabine Medium Day 1 Low day 8 September 2020
Non small cell lung cancer metastatic cISplatin and pemetrexed Medium June 2022
Non small cell lung cancer metastatic cISplatin and vinORELBine Medium September 2022
Non small cell lung cancer metastatic ciSplatin, pemetrexed and pembrolizumab
Medium June 2022
Non small cell lung cancer locally advanced or metastatic crizotinib Low March 2022
Non small cell lung cancer metastatic DOCEtaxel three weekly Medium September 2020
Non small cell lung cancer metastatic erlotinib Low March 2022
Non small cell lung cancer metastatic gefitinib Low March 2022
Non small cell lung cancer metastatic pemetrexed 
Low 1 June 2022
Non small cell lung cancer metastatic vinORELBine (intravenous)
The SA Health Cancer Drug Committee endorses the substitution of oral vinORELBine for this single agent protocol for suitable patients
Medium September 2020
Non small cell lung cancer metastatic vinORELBine (oral) Low March 2021
Non-small cell lung cancer metastatic pembrolizumab
Low March 2022
Non small cell lung cancer superior sulcus (Pancoast) cISplatin and etoposide chemoradiation pre-operative Medium September 2022

Small cell lung cancer

Protocol Administration at chemotherapy unit level Review date
Small cell lung cancer advanced topotecan (modified) Medium March 2020
Small cell lung cancer extensive disease cARBOplatin and etoposide Medium September 2020
Small cell lung cancer extensive disease cARBOplatin and oral etoposide

Medium Day 1 Low day 2 and 3

March 2021
Small cell lung cancer extensive disease CAV (CYCLOPHOSPHamide DOXOrubicin vinCRISTine) Medium September 2022
Small cell lung cancer extensive disease ciSplatin and irinotecan Medium September 2022
Small cell lung cancer limited disease cARBOplatin and etoposide Medium March 2020
Small cell lung cancer limited disease cISplatin and etoposide Medium September 2020
Small cell lung cancer limited disease cISplatin and etoposide chemoradiation Medium 3 March 2021

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Local radiotherapy services required
  4. Non-formulary drug included in the protocol
  5. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.

^ Back to top